Why Fisher & Paykel Healthcare (NZSE:FPH) Is Up 10.8% After Strong FY26 Profit And Higher Dividend

• Fisher & Paykel Healthcare recently reported full-year results to March 31, 2026, with sales rising to NZ$2,308.4 million and net income reaching NZ$468.5 million, alongside basic earnings per share of NZ$0.798.
• The company also declared a six‑month dividend of NZ$0.38823529 per share, highlighting a continued focus on returning cash to shareholders as earnings grow.
• We’ll now examine how this stronger full-year profitability, alongside the increased dividend, shapes Fisher & Paykel Healthcare’s existing investment narrative.

This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

Fisher & Paykel Healthcare Investment Narrative Recap

To own Fisher & Paykel Healthcare, you need to be comfortable with a premium-priced medical devices business that relies on long term demand for respiratory care in both hospitals and home settings. The latest full year result, with higher sales and net income, appears to support the near term earnings catalyst, while the biggest current risk remains margin pressure from tariffs, competition and hospital budget constraints, which this result does not materially remove.

The NZ$0.38823529 per share six month dividend for the period to 31 March 2026 ties directly into the profit uplift just reported, and matters if you care about income as well as growth. It connects the earnings result to a tangible cash outcome, but also raises the question of how sustainable dividend growth is if revenue momentum or margins were to soften in future years.

Yet despite stronger recent numbers, investors should be aware that tariff pressures could still materially affect...

Read the full narrative on Fisher & Paykel Healthcare (it's free!)

Fisher & Paykel Healthcare's narrative projects NZ$3.0 billion revenue and NZ$682.5 million earnings by 2029. This requires 11.9% yearly revenue growth and about a NZ$245.5 million earnings increase from NZ$437.0 million today.

Uncover how Fisher & Paykel Healthcare's forecasts yield a NZ$40.59 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming revenue of about NZ$2.9 billion and earnings near NZ$623.1 million by 2028, so their more pessimistic story about margins and tariffs may evolve after this latest NZ$2,308.4 million result.

Explore 6 other fair value estimates on Fisher & Paykel Healthcare - why the stock might be worth 41% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Fisher & Paykel Healthcare research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Fisher & Paykel Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fisher & Paykel Healthcare's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com